Skip to main content
| News

docdok.health involved in coronavirus research project

22.02.2021

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

img: docdok.health

According to a media release, the new research project on the effects of coronavirus infection has been launched by the CAir Konsortium, which includes the University Hospital Zurich (USZ) and the Swiss Federal Institute of Technology in Zurich (ETH) in addition to docdok.health, among others. The media release from docdok.health states that the project is also being supported by AstraZeneca Switzerland. With this, the research partners hope to investigate “the improvement in symptoms, lung function and quality of life in persons who have been hospitalized due to a coronavirus (specifically SARS-CoV-2) infection and the related severe lung disease to lung failure.”

For this, patients were surveyed after being discharged from the USZ using a docdok.health smartphone app, and a home monitoring system was implemented to follow-up patients. This system consists of “a lung function measuring device, an activity wristband, an air quality monitor, and a smartphone.” This system, called CAir Desk, was originally developed for the long-term care of patients with chronic lung disease.

Physicians from the USZ are able to study the data from both approaches at their place of work. For this, the data is prepared by docdok.health and presented clearly on an appropriate user interface. The company based in Basel was founded in 2017 and develops solutions to drive forward utility-based healthcare. The platform they have developed can collect and prepare patient-generated health data. This platform is already in use in five countries both for routine clinical applications and studies.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.